<DOC>
	<DOC>NCT00795821</DOC>
	<brief_summary>The purpose of this study is to assess whether LY2216684 is superior to placebo in the treatment of adult patients with major depressive disorder.</brief_summary>
	<brief_title>A Study in Adult Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<criteria>Adults age 1865 years Meet criteria for MDD as defined by DSMIVTR criteria without psychotic features Women of childbearing potential must test negative for pregnancy and agree to use a reliable method of birth control Grid Hamilton Rating Scale for Depression (GRIDHAMD17) total score &gt;=18 at visit 1 and visit 2 CGIS score &gt;=4 at visit 1 and visit 2 Are currently involved in or discontinued within the last 30 days from a clinical trial involving an offlabel use of an investigational drug Have previously completed or withdrawn from this study or any other study investigating LY2216684 Have had or currently have any additional ongoing DSMIVTR Axis 1 condition other than MDD Have had any anxiety disorder preceding the onset of depression that was considered the primary diagnosis within 1 year of visit 1 Have an Axis II disorder which would interfere with compliance with the protocol Have a current or previous diagnosis of Bipolar I or II, psychotic depression, schizophrenia or other psychotic disorder Have a history of substance abuse within the past 1 year Women who are pregnant or breastfeeding Have had a lack of response of the current depressive episode to 2 or more adequate courses of antidepressant therapy, or in the judgement of the investigator considered to have treatment resistant depression Patients who are judged to be at serious suicidal risk Have a serious or unstable medical illness Have any diagnosed medical condition which could be exacerbated by noradrenergic agents including unstable hypertension, unstable heart disease, tachycardia or tachyarrhythmia, narrow angle glaucoma, or urinary hesitation or retention Have received treatment with a MAOI within 14 days prior to visit 1 Have a history of severe allergies to more than 1 class of medication or multiple adverse drug reactions Have a history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) or psychosurgery within the last year Have a history of any seizure disorder (other than febrile seizures) Require psychotropic medication other than sedative/hypnotic medication for sleep Have a thyroid stimulating hormone (TSH ) level outside the established reference range. Are taking or have received treatment with any excluded medication within 7 days prior to visit 2 Initiation or change in intensity of psychotherapy or other nondrug therapies within 6 weeks prior to enrollment A positive urine drug screen for any substance of abuse at visit 1 Have initiate or discontinued hormone therapy within the previous 3 months prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>